• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

December 6, 2019

Tech Letter

Mad Hedge Technology Letter
December 6, 2019
Fiat Lux

Featured Trade:

(AUGMENTED REALITY IS HEATING UP),
(AAPL), (LITE), (QCOM), (NVDA), (ADSK), (FB), (MSFT), (SNAP)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-06 08:04:312019-12-06 08:45:44December 6, 2019
Mad Hedge Fund Trader

Augmented Reality is Heating Up

Tech Letter

First, what is augmented reality for all the newbies?

Augmented reality is an interactive experience of a real-world environment where the objects that reside in the real world are enhanced by computer-generated perceptual information, sometimes across multiple sensory modalities.

Augmented reality (AR) went rival in 2016 when the Pokemon Go mania captivated everyone from children to adults.

No sooner than 2021, the AR addressable market is poised to mushroom to $83 billion - a sizeable increase from the $350 million in 2018.

Much like machine learning, corporations are learning to marry up this technology with their existing products supercharging the performance.

Ulta Beauty, for example, has acquired AR and artificial intelligence start-ups to help customers digitally test the final appearance of makeup before users purchase the product.

That is just one micro example of what can and will be achieved.

Looking deeper into the guts, Qualcomm (QCOM) is hellbent on making their chips a critical part of the puzzle.

The company is better known for a telecom and a semiconductor play, not often lumped in with a list of AR stocks.

Qualcomm is strategically positioned to capitalize on the integration of augmented reality in mainstream corporate business embedding their chips into the devices.

Maximizing Qualcomm’s future role in the industry, the company announced in 2018 that it would be developing a chipset specifically for AR and VR applications.

This broad-based solution will make it easier for other developers to bring new glasses to the marketplace.

Autodesk (ADSK) is one of my favorite software stocks and a best of breed of industry design.

They sell 3D rendering software to designers and creators by offering a platform in which they can transform 2D designs into digital models that are both interactive and immersive, creating compelling experiences for end-users.

Autodesk has an array of powerful software suites to augment virtually any application, such as 3ds Max, a 3D modeling program; Maya LT game development software; its automotive modeling program VRED; and Forge, a development platform for cloud-based design.

Facebook (FB) has been piling capital into AR for years.

CEO Mark Zuckerberg wants to create an alternative profit-driver and is desperate to wean his brainchild from the digital ad circus.

One example is Facebook’s Portal TV and its Spark AR which is the platform responsible for mobile augmented reality experiences on Facebook, Messenger, and Instagram.

It supplies the virtual effects for consumers to play around with, but it is yet to be seen if consumers gravitate towards this product.

Lumentum (LITE) is the leader in 3D-sensing markets developing cloud and 5G wireless network deployments.

They manufacture 3D sensor lasers that can be used with smartphones to turn handsets into a sort of radar. Sensors are clearly a huge input in how AR functions along with the chips.

CEO of Apple (AAPL) Tim Cook put it best when he earlier said, “I do think that a significant portion of the population of developed countries, and eventually all countries, will have AR experiences every day, almost like eating three meals a day, it will become that much a part of you.”

He said that in 2016 and AR has yet to mushroom into the game-changing sector initially thought partly because the roll-out of 5G is taking longer than first expected.

Apple consumers will need to then adopt a 5G device or phone to really get the AR party started and that won’t happen until the backend of next year.

My initial channel checks hint that the Cupertino firm is planning a 5.4-inch model, two 6.1-inch devices, and one 6.7-inch phone, all of which will support 5G connectivity.

I surmise that Apple’s two premium devices will feature “world-facing” 3D sensing, a technology that could help Apple boost its augmented-reality capabilities and support other feature improvements on its priciest devices.

Apple has had a big hand in Lumentum's growth and will continue to buy their sensors, but other key component suppliers will get contracts such as Finisar, a manufacturer of optical communication components and subsystems.

Apple planned to debut AR glasses by 2020, but the rollout is now delayed until 2022.

They are clearly on the back foot with Microsoft (MSFT) further along in the process.

Microsoft already has a second iteration of its AR headset, HoloLens, and is compatible with several apps and has integration with Azure as well.

The head start of 2 years could really make a meaningful impact and might be hard for Apple to recover.

Facebook isn’t the only social media company going full steam into AR, Snap (SNAP) recently unveiled its newest spectacles, which feature AR elements.

Another application of AR is autonomous driving with Nvidia working on improving the driving experience by fusing AR with artificial intelligence.

Nvidia (NVDA) is already thinking about the next generation of AR technologies with varifocal displays, which improve the clarity of an object for a user.

It will take time to transform our relationship with AR, the infrastructure is still getting built out and many people just don’t have a device that will allow us to tap into the technology.

Investors must know that AR-related stocks will start to appreciate from the anticipation of full sale adoption and there could be a killer app that forces the mainstream user to take notice.

Until then, companies jockey for position and hope to be the ones that take the lion’s share of the revenue once the technology goes into overdrive.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/AR.png 541 833 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-06 08:02:302020-05-11 13:00:35Augmented Reality is Heating Up
Mad Hedge Fund Trader

December 6, 2019 - Quote of the Day

Tech Letter

“If you think you deserve a raise, you should just ask.” – Said CEO of Microsoft Satya Nadella

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/satya.png 302 435 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-06 08:00:262019-12-06 08:45:03December 6, 2019 - Quote of the Day
Mad Hedge Fund Trader

December 5, 2019 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-05 09:24:292019-12-05 09:24:29December 5, 2019 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

December 5, 2019

Diary, Newsletter, Summary

Global Market Comments
December 5, 2019
Fiat Lux

Featured Trade:

(MY 20 RULES FOR TRADING IN 2020)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-05 04:04:192019-12-04 16:52:14December 5, 2019
Mad Hedge Fund Trader

December 5, 2019

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
December 5, 2019
Fiat Lux

Featured Trade:

(WHY 1 + 1 = 4 WITH THE BRISTOL MYERS/CELGENE MERGER),
(BMY), (CELG), (AMGN)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-05 04:02:342019-12-04 16:12:59December 5, 2019
Mad Hedge Fund Trader

My 20 Rules for Trading in 2020

Diary, Newsletter

There's nothing like starting the new year with going back to basics and reviewing the rules that worked so well for us in 2019. Call this the refresher course for Trading 101.

I usually try to catch three or four trend changes a year, which might generate 100-200 trades, and often come in frenzied bursts.

Since I am one of the greatest tightwads that ever walked the planet, I only like to buy positions when we are at the height of despair and despondency, and traders are raining off the Golden Gate Bridge like a winter downpour.

Similarly, I only like to sell when the markets are tripping on steroids and ecstasy and are convinced that they can live forever.

Some 99% of the time, the markets are in the middle, and there is nothing to do but deep research and looking for the next trade. That is the purpose of this letter.

Over the five decades that I have been trading, I have learned a number of tried and true rules which have saved my bacon countless times. I will share them with you today.

1) Don’t over trade. This is the number one reason why individual investors lose money. Look at your trades of the past year and apply the 90/10 rule. Dump the least profitable 90% and watch your performance skyrocket. Then aim for that 10%. Overtrading is a great early retirement plan for your broker, not you.

2) Always use stops. Risk control is the measure of the good hedge fund trader. If you lose all your capital on the lemons, you can’t play when the great trades set up. Consider cash as having an option value.

3) Don’t forget to sell. Date, don’t marry your positions. Remember, hogs get fed and pigs get slaughtered. My late mentor, Barton Biggs, told me to always leave the last 10% of a move for the next guy.

4) You don’t have to be a genius to play this game. If that was required, Wall Street would have run out of players a long time ago.

If you employ risk control and stops, then you can be wrong 40% of the time, and still make a living. That’s a little better than a coin toss. If you are wrong only 30% of the time, you can make millions.

If you are wrong a scant 20% of the time, you are heading a trading desk at Goldman Sachs. If you are wrong a scant 10% of the time, you are running a $20 billion hedge fund that the public only hears about when you pay $100 million for a pickled shark at a modern art auction.

If someone says they are never wrong, as is often claimed on the Internet, run a mile because it is impossible. By the way, I was wrong 15% of the time in 2013. That’s what you’re paying for.

5) This is hard work. Trading attracts a lot of wide-eyed, naïve but lazy people because it appears so easy from the outside. You buy a stock, watch it go up, and make money. How hard is that?

The reality is that successful investing requires twice as much work as a normal job. The more research you put into a trade, the more comfortable you will become, and the more profitable it will be. That’s what this letter is for.

6) Don’t chase the market. If you do, it will turn back and bite you. Wait for it to come to you. If you miss the train, there will be another one along in minutes, hours, days, weeks, or months. Patience is a virtue.

7) Limit Your Losses. When I put on a position, I calculate how much I am willing to lose to keep it. I then put a stop just below there. If I get triggered, I just walk away. Emotion never enters the equation.

Only enter a trade when the risk/ reward is in your favor. You can start at 3:1. That means only risk a dollar to potentially make three.

8) Don’t confuse a bull market with brilliance. I am not smart, just old as dirt.

9) Tape this quote from the great economist and early hedge fund trader of the 1930s, John Maynard Keynes, to your computer monitor: "Markets can remain illogical longer than you can remain solvent." Hang around long enough, and you will see this proven time and again (ten-year Treasuries at 1.38%?!).

10) Don’t believe the media. I know, I used to be one of them. Look for the hard data, the numbers, and you’ll see that often the talking heads, the paid industry apologists, and politicians don’t know what they are talking about (the Gulf oil spill will create a dead zone for decades?)

Average out all the public commentary, and half are bullish and half bearish at any given time. The problem is that they never tell you which one is right (that is my job). When they all go one way, the markets usually go the opposite direction.

11) When you are running a long/short portfolio, 80% of your time is spent managing the shorts. If you don’t want to do the work, then cash beats a short any day of the week.

12) Sometimes the conventional wisdom is right.

13) Invest like a fundamentalist, execute like a technical analyst. This is what all the pros do.

14) Use technical analysis only, and you will buy every rally, sell every dip, and end up broke. That said, learn what an “outside reversal” is, and who the hell is that Italian guy, Leonardo Fibonacci.

15) The simpler a market approach, the better it works. Everyone talks about “buy low and sell high”, but few actually do it. All black boxes eventually blow up, if they were ever there in the first place.

16) Markets are made up of people. Understand and anticipate how they think, and you will know what the markets are going to do.

17) Understand what information is in the market and what isn’t and you will make more money.

18) Do the hard trade, the one that everyone tells you that you are “Mad” to do. If you add a position and then throw up on your shoes afterwards, then you know you’ve done the right thing. This is why people started calling me “Mad” 40 years ago. (What? Tech stocks were a huge buy the first week of January?).

19) If you are trying to get out of a hole, the first thing to do is quit digging and throw away the shovel. Sell everything. A blank position sheet can be invigorating and illuminating.

20) Making money in the market is an unnatural act, and fights against the tide of evolution.

We humans are predators and hunters evolved to track game on the horizon of an African savanna. Modern humans are maybe 5 million years old, but civilization has been around for only 10,000 years.

Our brains have not had time to make the adjustment. In the market, this means that if a stock has gone up, you believe it will continue to do so.

This is why market tops and bottoms see volume spikes. To make money, you have to go against these innate instincts.

Some people are born with this ability, while others can only learn it through decades of training. I am in the latter group.

 

Great Hunter, Lousy Trader

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/02/bridge.png 327 364 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-05 04:02:012019-12-04 17:17:49My 20 Rules for Trading in 2020
Mad Hedge Fund Trader

Why 1 + 1 = 4 With the Bristol-Myers/Celgene Merger

Biotech Letter

The treasure trove of Bristol-Myers Squibb’s (BMY) growth products expanded considerably following the completion of its $74 billion merger with Celgene (CELG). This deal marks the end of a long chapter in the industry’s history, as Celgene, founded way back in 1986, was one of the first biotech companies created.

From a financial standpoint, the combined company is hailed as one of the most exciting powerhouses of profitability until at least 2023. As things stand, the newly minted biotech behemoth is trading at roughly nine times forward earnings.

The current company also offers an attractive dividend yield of 2.9% -- and that’s not even the best part of the news. The most exciting part of the deal is the fact that the new company now owns one of the most valuable oncology franchises in the biotech sector.

Under the terms, Celgene shareholders got the following for every share: 1.00 share of BMY common, cash worth $50 without interest, and one Contingent Value Right (CVR) they can trade. If they choose to not trade it, then the Celgene shareholder will receive payment of $9 in cash depending on future milestones achieved. As for (BMY), the company received $13.4 billion following Celgene’s sale of blockbuster psoriasis and psoriatic arthritis drug Otezla to Amgen (AMGN) as part of regulatory requirements.

The CVRs are contingent on three drugs in Celgene’s pipeline. One is the multiple sclerosis treatment Ozanimod. Another is a liso-cel lymphoma drug, which is expected to get the green light by December 31, 2020. The third is multiple myeloma treatment bb2121, which is eyed for approval by March 31, 2021.

Ozanimod actually has a high chance of winning an FDA approval by early 2020. The drug’s peak annual sales is expected to be in the ballpark of $5 billion. Meanwhile, Celgene’s liso-cel treatments are anticipated to rake in an additional $4 billion or so in annual sales. The company’s recently approved Reblozyl is also estimated to tack on another $2 billion in peak sales. 

Celgene’s CelMOD treatments, which are in their early-stage clinical studies, could be massive moneymakers as well. Another cell therapy under development with Massachusetts-based gene therapy developer bluebird bio (BLUE), bb21217, is also projected as a big winner.

While the Celgene cancer pipeline is promising, the company came into this union with a number of already top-selling oncology drugs like multiple myeloma medication Revlimid as well as blood cancer treatments Inrebic and Pomalyst.

As for BMY, the biopharma giant also has its own high-profile lineup led by leukemia target therapy Sprycel, atrial fibrillation treatment Eliquis, advanced stage lung cancer injection Opdivo, and metastatic melanoma treatment Yervoy.

In fact, Opdivo and Eliquis are projected to rank as among the highest-selling drugs globally in the succeeding years.

Although some BMY investors are voicing concerns over the impending sales decline for Revlimid courtesy of generic rivals by 2022, Celgene’s new candidates and already top-performing drugs could still give the combined company a firm growth runway.

Hence, BMY and Celgene have effectively built a prodigious economic moat that practically eliminates any fear of competition in several crucial areas. This is not to say that particular products won’t experience the usual rise and fall in sales. It simply means that BMY’s overall oncology portfolio wouldn’t exactly encounter major problems when it comes to income generation and growth in the years to come.

In a broader sense, the newly formed company should be able to withstand any slowing down in the economy. Cancer patients need continuous medication, and it’s highly unlikely that they would choose to put a stop to their treatment simply because the economy is taking a downturn. Consequently, this makes BMY one of the safest plays in the market right now.

Keep buying (BMY) on dips. There is far to go.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/bmy.png 470 899 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-05 04:00:502019-12-04 16:11:50Why 1 + 1 = 4 With the Bristol-Myers/Celgene Merger
Mad Hedge Fund Trader

December 4, 2019

Diary, Newsletter, Summary

Global Market Comments
December 4, 2019
Fiat Lux

Featured Trade:

(THE DEATH OF KING COAL),
(KOL), (PEA),
(THE BRAVE NEW WORLD OF ONLINE RETAILING),
(SNAP), (GPRO), (APRN), (SFIX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-04 11:06:312019-12-04 11:18:45December 4, 2019
Mad Hedge Fund Trader

December 4, 2019

Tech Letter

Mad Hedge Technology Letter
December 4, 2019
Fiat Lux

Featured Trade:

(THE RUSH TO BUY ONLINE),
(AMZN), (WMT), (TGT), (W), (ETSY), (SHOP), (ADOBE)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-04 10:04:272019-12-04 10:20:10December 4, 2019
Page 11 of 173«‹910111213›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top